Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ischemic Heart Disease
  Free Subscription

Articles published in
N Engl J Med
    July 2024
  1. BOHM F, James S
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. Reply.
    N Engl J Med. 2024;391:288.
    >> Share

  2. LI P
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
    N Engl J Med. 2024;391:287-288.
    >> Share

  3. YNDIGEGN T, Hofmann R, Jernberg T
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. Reply.
    N Engl J Med. 2024;391:95.
    >> Share

  4. KOMAMURA K, Kobayashi K, Iwase M
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024;391:94-95.
    >> Share

  5. CLELAND JGF, McMurray JJV, Freemantle N
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024;391:94.
    >> Share

    June 2024
  6. MOLLER JE, Hassager C
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. Reply.
    N Engl J Med. 2024;390:2328-2330.
    >> Share

  7. VON LEWINSKI D, Herold L, Toth GG
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2328.
    >> Share

  8. BALDETTI L, Pieri M, Scandroglio AM
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2328.
    >> Share

  9. ELKARYONI A, Hyder O, Saad M
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2327.
    >> Share

  10. FROM AM
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2327.
    >> Share

  11. MALLIDI J, Lotfi A
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2326-2327.
    >> Share

  12. THIELE H, Desch S, Zeymer U
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2325-2326.
    >> Share

  13. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    >> Share

  14. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    >> Share

  15. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    >> Share

  16. LI S, Gu HQ, Li H, Wang X, et al
    Reteplase versus Alteplase for Acute Ischemic Stroke.
    N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2400314.
    >> Share

  17. XIONG Y, Campbell BCV, Schwamm LH, Meng X, et al
    Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
    N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2402980.
    >> Share

  18. MAHENDIRAN T, Collet C, De Bruyne B
    Coronary-Artery Autoregulation with Increasing Stenosis.
    N Engl J Med. 2024;390:2030-2032.
    >> Share

    May 2024
  19. KING G, Hamilton GW
    Left Ventricular Thrombus after Anterior Myocardial Infarction.
    N Engl J Med. 2024;390:e50.
    >> Share

  20. NATARAJAN P
    Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMe2405647.
    >> Share

  21. ALBERS GW, Purdon B, Campbell BCV
    Tenecteplase for Stroke at 4.5 to 24 Hours. Reply.
    N Engl J Med. 2024;390:1729.
    >> Share

  22. GOYAL M, Bosshart SL, Ospel JM
    Tenecteplase for Stroke at 4.5 to 24 Hours.
    N Engl J Med. 2024;390:1729.
    >> Share

  23. GRINSPOON SK, Ribaudo HJ, Douglas PS
    Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.
    N Engl J Med. 2024;390:1626-1628.
    >> Share

    April 2024
  24. STEG PG
    Routine Beta-Blockers in Secondary Prevention - On Injured Reserve.
    N Engl J Med. 2024;390:1434-1436.
    >> Share

  25. RAO SV
    Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress.
    N Engl J Med. 2024;390:1436-1438.
    >> Share

  26. MOLLER JE, Engstrom T, Jensen LO, Eiskjaer H, et al
    Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:1382-1393.
    >> Share

  27. BOHM F, Mogensen B, Engstrom T, Stankovic G, et al
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
    N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMoa2314149.
    >> Share

  28. KUNADIAN V
    Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome.
    N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMe2403527.
    >> Share

  29. YNDIGEGN T, Lindahl B, Mars K, Alfredsson J, et al
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479.
    >> Share

  30. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
    >> Share

  31. GIBSON CM, Duffy D, Korjian S, Bahit MC, et al
    Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2400969.
    >> Share

  32. ROULEAU J
    Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
    >> Share

  33. BUTLER J, Jones WS, Udell JA, Anker SD, et al
    Empagliflozin after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
    >> Share

  34. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    >> Share

    March 2024
  35. WHITE HD
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:10.
    >> Share

  36. AL-LAMEE RK, Rajkumar CA
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:1151-1152.
    >> Share

  37. DURANTE A, Baiardo Redaelli M
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150-1151.
    >> Share

  38. SHERROD CF 4TH, O'Keefe EL, Ikemura N
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150.
    >> Share

  39. BESTERMANN WH JR
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1149-1150.
    >> Share

  40. ROSWELL RO, Wong MP, Stefanescu Schmidt AC, Petranovic M, et al
    Case 8-2024: A 55-Year-Old Man with Cardiac Arrest, Cardiogenic Shock, and Hypoxemia.
    N Engl J Med. 2024;390:1030-1043.
    >> Share

  41. CARSON JL, Brooks MM, Hebert PC
    Transfusion Strategy in Myocardial Infarction and Anemia. Reply.
    N Engl J Med. 2024;390:961-962.
    >> Share

  42. KHAN MS, Spertus JA, Chan PS
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960-961.
    >> Share

  43. CHAPALAIN X, Aubron C
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960.
    >> Share

  44. MARFELLA R, Prattichizzo F, Sardu C, Fulgenzi G, et al
    Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
    N Engl J Med. 2024;390:900-910.
    >> Share

    February 2024
  45. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    >> Share

  46. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    >> Share

  47. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    >> Share

  48. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    >> Share

  49. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    >> Share

  50. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    >> Share

  51. ALBERS GW, Jumaa M, Purdon B, Zaidi SF, et al
    Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection.
    N Engl J Med. 2024 Feb 8. doi: 10.1056/NEJMoa2310392.
    >> Share

  52. LEIFER D
    Tenecteplase for Stroke - Opening the Window?
    N Engl J Med. 2024 Feb 8. doi: 10.1056/NEJMe2314930.
    >> Share

    January 2024
  53. SPATZ ES, Ginsburg GS, Rumsfeld JS, Turakhia MP, et al
    Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine.
    N Engl J Med. 2024;390:346-356.
    >> Share

  54. THIELE H, Desch S, Zeymer U
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. Reply.
    N Engl J Med. 2024;390:190-191.
    >> Share

  55. SCHOLZ KH, Meyer T
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:190.
    >> Share

  56. D'AMICO F, Pruna A, D'Andria Ursoleo J
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:190.
    >> Share

  57. BARDY T, Didier C, Mongardon N
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:189-190.
    >> Share

  58. STAHLI BE, Ruschitzka F
    Timing of Complete Revascularization for Myocardial Infarction. Reply.
    N Engl J Med. 2024;390:92.
    >> Share

  59. DEN DEKKER WK, Elscot JJ, Diletti R
    Timing of Complete Revascularization for Myocardial Infarction.
    N Engl J Med. 2024;390:91-92.
    >> Share

  60. OKHOTIN A, Barchuk A
    Timing of Complete Revascularization for Myocardial Infarction.
    N Engl J Med. 2024;390:91.
    >> Share

    December 2023
  61. BLOCH EM, Tobian AAR
    Optimizing Blood Transfusion in Patients with Acute Myocardial Infarction.
    N Engl J Med. 2023;389:2483-2485.
    >> Share

  62. WHITE HD
    Changing the Orbit around Percutaneous Coronary Intervention for Stable Angina.
    N Engl J Med. 2023;389:2387-2388.
    >> Share

  63. MAGNUSSEN C, Leong DP, Blankenberg S
    Modifiable Risk Factors and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2023;389:2401-2402.
    >> Share

  64. FIGTREE GA, Gray MP, Channon KM
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2401.
    >> Share

  65. MEI Z, Pu J, Zheng D
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2400-2401.
    >> Share

  66. OU D, Hu C, Huang S
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2400.
    >> Share

    November 2023
  67. GRINSPOON SK, Ribaudo HJ, Douglas PS
    Pitavastatin and Cardiovascular Disease in HIV. Reply.
    N Engl J Med. 2023;389:e46.
    >> Share

  68. OLALLA J, Pombo M
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    >> Share

  69. IOANNOU P, Filippatos TD, Kofteridis DP
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    >> Share

  70. ALAM SR, Mureithi M, Ferrand R
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    >> Share

  71. BOETTIGER DC, Phillips AN, Newall AT
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    >> Share

  72. BISCAGLIA S, Campo G
    Complete or Culprit-Only PCI in Older Patients with MI. Reply.
    N Engl J Med. 2023;389:1924.
    >> Share

  73. MONE P, Guerra G, Santulli G
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1923-1924.
    >> Share

  74. SANCHIS J, Ariza-Sole A, Alfonso F
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1923.
    >> Share

  75. DURAI V, Mallidi J
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1922.
    >> Share

  76. MADSEN JM, Engstrom T
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1922-1923.
    >> Share

  77. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    >> Share

  78. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    >> Share

  79. CARSON JL, Brooks MM, Hebert PC, Goodman SG, et al
    Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307983.
    >> Share

  80. RAJKUMAR CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, et al
    A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2310610.
    >> Share

    October 2023
  81. HOLM NR, Andreasen LN, Neghabat O, Laanmets P, et al
    OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions.
    N Engl J Med. 2023;389:1477-1487.
    >> Share

  82. JONES WS
    Timing Is Everything - Evidence for When to Perform Complete Revascularization in STEMI.
    N Engl J Med. 2023;389:1427-1428.
    >> Share

  83. JOSEPH P, Yusuf S
    Coordinating Efforts to Reduce the Global Incidence of Cardiovascular Disease.
    N Engl J Med. 2023;389:1329-1331.
    >> Share

    September 2023
  84. BHASIN S, Lincoff AM, Nissen SE
    Cardiovascular Safety of Testosterone-Replacement Therapy. Reply.
    N Engl J Med. 2023;389:1150-1151.
    >> Share

  85. GROSSMANN M, Zajac JD
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1149-1150.
    >> Share

  86. MALOZOWSKI S, Reboussin DM
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1149.
    >> Share

  87. HUANG Y, Shen B, Zhou YF
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1148-1149.
    >> Share

    August 2023
  88. STAHLI BE, Varbella F, Linke A, Schwarz B, et al
    Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2307823.
    >> Share

  89. ALI ZA, Landmesser U, Maehara A, Matsumura M, et al
    Optical Coherence Tomography-Guided versus Angiography-Guided PCI.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2305861.
    >> Share

  90. BISCAGLIA S, Guiducci V, Escaned J, Moreno R, et al
    Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2300468.
    >> Share

  91. MEHTA SR
    Complete Revascularization in Older Patients with Myocardial Infarction.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMe2307941.
    >> Share

  92. MAGNUSSEN C, Ojeda FM, Leong DP, Alegre-Diaz J, et al
    Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2206916.
    >> Share

  93. THIELE H, Zeymer U, Akin I, Behnes M, et al
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2307227.
    >> Share


  94. Preventing HIV's Collateral Cardiovascular Damage.
    N Engl J Med. 2023;389:e11.
    >> Share

    July 2023
  95. GRINSPOON SK, Fitch KV, Zanni MV, Fichtenbaum CJ, et al
    Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.
    N Engl J Med. 2023 Jul 23. doi: 10.1056/NEJMoa2304146.
    >> Share

  96. FREIBERG MS
    HIV and Cardiovascular Disease - An Ounce of Prevention.
    N Engl J Med. 2023 Jul 23. doi: 10.1056/NEJMe2306782.
    >> Share

    June 2023
  97. NISSEN SE, Nicholls SJ, Lincoff AM
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2023;388:2489-2490.
    >> Share

  98. AMARENCO P
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488-2489.
    >> Share

  99. STEINACHER E, Sulzgruber P, Niessner A
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488.
    >> Share

  100. SPACEK L
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488.
    >> Share

  101. LOPEZ-AYALA P, Glarner N, Mueller C
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2487-2488.
    >> Share

  102. LINCOFF AM, Bhasin S, Flevaris P, Mitchell LM, et al
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023 Jun 16. doi: 10.1056/NEJMoa2215025.
    >> Share

    May 2023
  103. LEE JM, Choi KH, Song YB, Lee JY, et al
    Intravascular Imaging-Guided or Angiography-Guided Complex PCI.
    N Engl J Med. 2023;388:1668-1679.
    >> Share

    April 2023
  104. ISHANI A, Cushman WC, Leatherman SM
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. Reply.
    N Engl J Med. 2023;388:1342.
    >> Share

  105. FRAVEL MA, Ernst ME
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
    N Engl J Med. 2023;388:1342.
    >> Share

  106. MESSERLI FH
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
    N Engl J Med. 2023;388:1341-1342.
    >> Share

    March 2023
  107. JABAGI MJ, Bertrand M, Botton J, Le Vu S, et al
    Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
    N Engl J Med. 2023 Mar 29. doi: 10.1056/NEJMc2302134.
    >> Share

  108. OLIVA-DAMASO N, Perazella MA
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2023;388:955.
    >> Share

  109. VAN REGEMORTER E, Jadoul M, Gillion V
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2023;388:954-955.
    >> Share

  110. KEANEY JF JR
    Bempedoic Acid and the Prevention of Cardiovascular Disease.
    N Engl J Med. 2023 Mar 4. doi: 10.1056/NEJMe2300793.
    >> Share

  111. NISSEN SE, Lincoff AM, Brennan D, Ray KK, et al
    Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
    N Engl J Med. 2023 Mar 4. doi: 10.1056/NEJMoa2215024.
    >> Share

    January 2023
  112. PERERA D, Ryan M, O'Kane PD
    PCI for Ischemic Left Ventricular Dysfunction. Reply.
    N Engl J Med. 2023;388:188-189.
    >> Share

  113. ALFONSO F, Cuesta J, Diez-Villanueva P
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:188.
    >> Share

  114. ANDREOTTI F, Chiariello GA, Massetti M
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:187-188.
    >> Share

  115. VIDAL-CALES P, Brugaletta S, Sabate M
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:187.
    >> Share

  116. DE SILVA K, Campbell T, Kumar S
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:186-187.
    >> Share

    December 2022
  117. GUSEH JS 2ND, Parakh A, Chen YE, Sundt TM, et al
    Case 40-2022: A 38-Year-Old Man with Exertional Chest Discomfort.
    N Engl J Med. 2022;387:2450-2460.
    >> Share

  118. MC CAUSLAND FR, Singh AK, Claggett BL, Carroll K, et al
    Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply.
    N Engl J Med. 2022;387:2482-2485.
    >> Share

  119. HUANG C, He Y, Li Y
    Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease.
    N Engl J Med. 2022;387:2482.
    >> Share

  120. ROJAS-RIVERA J, Carriazo S, Ortiz A
    Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease.
    N Engl J Med. 2022;387:2481-2482.
    >> Share

  121. ISHANI A, Cushman WC, Leatherman SM, Lew RA, et al
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
    N Engl J Med. 2022 Dec 14. doi: 10.1056/NEJMoa2212270.
    >> Share

  122. CASTELLANO JM, Cordero A, Fuster V
    Polypill Strategy in Secondary Cardiovascular Prevention. Reply.
    N Engl J Med. 2022;387:2197-2198.
    >> Share

  123. ZHANG Y, Zhu Z, Gao C
    Polypill Strategy in Secondary Cardiovascular Prevention.
    N Engl J Med. 2022;387:2197.
    >> Share

  124. CARNEY RM, Freedland KE
    Polypill Strategy in Secondary Cardiovascular Prevention.
    N Engl J Med. 2022;387:2197.
    >> Share

  125. STOSCHITZKY K
    Polypill Strategy in Secondary Cardiovascular Prevention.
    N Engl J Med. 2022;387:2196-2197.
    >> Share

    November 2022
  126. PARK DW, Kang DY, Park SJ
    Stress Testing in High-Risk Patients after PCI. Reply.
    N Engl J Med. 2022;387:e54.
    >> Share

  127. SHIOMI H
    Stress Testing in High-Risk Patients after PCI.
    N Engl J Med. 2022;387:e54.
    >> Share

  128. O'DONOGHUE ML, Rosenson RS, Gencer B, Lopez JAG, et al
    Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
    N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2211023.
    >> Share

  129. DAS PRADHAN A, Glynn RJ, Fruchart JC, MacFadyen JG, et al
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2210645.
    >> Share


  130. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction.
    N Engl J Med. 2022;387:1724.
    >> Share

    October 2022
  131. DESAI AS, Dudzinski DM, Stib MT, Chen ST, et al
    Case 32-2022: A 76-Year-Old Man with Postoperative Cardiogenic Shock and Diffuse Rash.
    N Engl J Med. 2022;387:1502-1513.
    >> Share

  132. PERERA D, Clayton T, O'Kane PD, Greenwood JP, et al
    Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2022;387:1351-1360.
    >> Share

    September 2022

  133. Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:1244.
    >> Share

  134. HONDA S, Kawasaki T
    Wellens' Syndrome.
    N Engl J Med. 2022;387:e25.
    >> Share

  135. RYDEN L, Standl E
    After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk.
    N Engl J Med. 2022;387:1136-1138.
    >> Share

  136. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    N Engl J Med. 2022;387:1075-1088.
    >> Share

  137. FUKAMACHI D, Okumura Y
    Giant Coronary-Artery Aneurysm.
    N Engl J Med. 2022;387:e23.
    >> Share

  138. PARK DW, Kang DY, Ahn JM, Yun SC, et al
    Routine Functional Testing or Standard Care in High-Risk Patients after PCI.
    N Engl J Med. 2022;387:905-915.
    >> Share

  139. TAMIS-HOLLAND JE
    Surveillance Stress Testing "POST-PCI" - A Future Class III Recommendation?
    N Engl J Med. 2022;387:941-942.
    >> Share

  140. KOO BK, Hu X, Kang J, Zhang J, et al
    Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI.
    N Engl J Med. 2022;387:779-789.
    >> Share

    August 2022
  141. LINDHOLT JS, Sogaard R, Rasmussen LM, Mejldal A, et al
    Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2208681.
    >> Share

  142. CASTELLANO JM, Pocock SJ, Bhatt DL, Quesada AJ, et al
    Polypill Strategy in Secondary Cardiovascular Prevention.
    N Engl J Med. 2022 Aug 26. doi: 10.1056/NEJMoa2208275.
    >> Share

  143. LESLIE BR, Gerwin LE
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:478.
    >> Share

  144. HEYMAN SN, Abassi Z
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:477-478.
    >> Share

  145. JACOBS DR JR, Sinaiko AR, Woo JG
    Childhood Risk Factors and Adult Cardiovascular Events. Reply.
    N Engl J Med. 2022;387:473-474.
    >> Share

  146. SCHUERMANS A, Lewandowski AJ
    Childhood Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022;387:473.
    >> Share

  147. WANG M, Zhou M, Feng Z
    Childhood Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022;387:472-473.
    >> Share

  148. ORTIZ A
    Childhood Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022;387:472.
    >> Share

    July 2022
  149. DODD JD, Kofoed KF, Dewey M
    CT or Invasive Coronary Angiography in Stable Chest Pain. Reply.
    N Engl J Med. 2022;387:379-380.
    >> Share

  150. GIBBONS RJ
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022;387:378.
    >> Share

  151. DANZI GB, Piccolo R
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022;387:378.
    >> Share

  152. BAUMANN AA, Roberts-Thomson RL, Psaltis PJ
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022;387:377-378.
    >> Share

  153. REDBERG R, Jeon D
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022;387:376-377.
    >> Share

    June 2022
  154. MA Y, Cook NR, Hu FB
    Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk. Reply.
    N Engl J Med. 2022;386:e60.
    >> Share

  155. IOANNOU A
    Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2022;386:e60.
    >> Share

  156. LIU L, Chen Y, Liu S
    Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2022;386:e60.
    >> Share

  157. INOUE K, Nishikawa T
    Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2022;386:e60.
    >> Share

    May 2022
  158. BRAUNWALD E
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;386:2024-2034.
    >> Share

  159. FEARON WF, Zimmermann FM, Pijls NHJ
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. Reply.
    N Engl J Med. 2022;386:1865-1866.
    >> Share

  160. FERLINI M, Munafo A, Visconti LO
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1865.
    >> Share

  161. FELDMAN D, Nicolas J, Dangas G
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1864-1865.
    >> Share

  162. ROSENBLUM AL, Pack QR
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1864.
    >> Share

  163. VAN BELLE E, Patel M, Davies J
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1863-1864.
    >> Share

  164. YTTERBERG SR, Bhatt DL, Connell CA
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply.
    N Engl J Med. 2022;386:1768.
    >> Share

  165. D'AMICO F, Peyrin-Biroulet L, Danese S
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1767-1768.
    >> Share

  166. LADAK K, Crowther M
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1766-1767.
    >> Share

  167. OZDEDE A, Yazici H
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1766.
    >> Share

    April 2022
  168. PITT B, Joseph A, Schloemer P
    Cardiovascular Events with Finerenone in CKD and Diabetes. Reply.
    N Engl J Med. 2022;386:e43.
    >> Share

  169. ORTIZ A, Sarafidis P, Ferro CJ
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    >> Share

  170. GERARD AO, Laurain A, Esnault VLM
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    >> Share

  171. KAO PH, Hsu LC
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    >> Share

  172. INGELFINGER JR
    Childhood Risk Factors and Prediction of Adult Cardiovascular End Points.
    N Engl J Med. 2022 Apr 4. doi: 10.1056/NEJMe2203743.
    >> Share

  173. JACOBS DR JR, Woo JG, Sinaiko AR, Daniels SR, et al
    Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022 Apr 4. doi: 10.1056/NEJMoa2109191.
    >> Share

    March 2022
  174. MAUROVICH-HORVAT P, Bosserdt M, Kofoed KF, Rieckmann N, et al
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022 Mar 4. doi: 10.1056/NEJMoa2200963.
    >> Share

  175. DEVEREAUX PJ, Lamy A, Chan MTV, Allard RV, et al
    High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality.
    N Engl J Med. 2022;386:827-836.
    >> Share

    February 2022
  176. PFEFFER MA, Jering KS, Braunwald E
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Reply.
    N Engl J Med. 2022;386:603.
    >> Share

  177. IOANNOU A
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2022;386:603.
    >> Share

    January 2022
  178. YTTERBERG SR, Bhatt DL, Mikuls TR, Koch GG, et al
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:316-326.
    >> Share

  179. FEARON WF, Zimmermann FM, De Bruyne B, Piroth Z, et al
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:128-137.
    >> Share

    December 2021

  180. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2021;385:2592.
    >> Share

  181. DESCH S, Freund A, Akin I, Behnes M, et al
    Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation.
    N Engl J Med. 2021;385:2544-2553.
    >> Share

  182. NEAL B, Tian M, Wu Y
    Salt Substitute and Cardiovascular Events and Death. Reply.
    N Engl J Med. 2021;385:2493-2494.
    >> Share

  183. BURSZTYN M
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2493.
    >> Share

  184. MORITA H, Komuro I
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2492-2493.
    >> Share

  185. ZUCCALA G, Laudisio A, Ciaburri M
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2492.
    >> Share

  186. GRAUDAL N, Jurgens G, Alderman MH
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2491-2492.
    >> Share

    November 2021
  187. MATHEW R, Di Santo P, Hibbert B
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. Reply.
    N Engl J Med. 2021;385:2108-2109.
    >> Share

  188. GIBSON LE, Chang MG, Berra L
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    N Engl J Med. 2021;385:2108.
    >> Share

  189. POTTER BJ
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    N Engl J Med. 2021;385:2107-2108.
    >> Share

  190. MA Y, He FJ, Sun Q, Yuan C, et al
    24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2021 Nov 13. doi: 10.1056/NEJMoa2109794.
    >> Share

  191. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2021;385:1845-1855.
    >> Share

  192. SINGH AK, Carroll K, McMurray JJV, Solomon S, et al
    Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113380.
    >> Share

  193. SINGH AK, Carroll K, Perkovic V, Solomon S, et al
    Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113379.
    >> Share

    October 2021
  194. VALGIMIGLI M, Frigoli E, Heg D, Tijssen J, et al
    Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
    N Engl J Med. 2021;385:1643-1655.
    >> Share


  195. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    N Engl J Med. 2021;385:1632.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016